Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
Year: 2015
Type: article
Abstract: Lung neuroendocrine tumors are a heterogeneous subtype of pulmonary cancers representing approximately 20% of all lung cancers, including small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). The frequency appears to be approximately 3% for LCNEC. Diagnosis of LCNEC requires attention to neuroendocrine features by light microscopy and confirmation by immunohistochemical staining for neuroendocrine markers. Both SCLC and pulmonary LCNEC are high-grade and poor-prognosis tumors, with higher incidence in males and smokers and peripheral localization. LCNEC is very rare, and the precise diagnosis on small specimens is very difficult, so we have still too few data to define a standard of treatment for pulmonary LCNECs. Data of literature, most based on retrospective analysis, indicated a poor 5-year overall survival, with a high incidence of recurrence after surgery, even in stage I disease. Primary surgery should be the first option in all operable patients because there is no validate therapeutic approach for LCNEC due to lack of clinical trials in this setting. Neoadjuvant platinum-based regimens remain only an option for potentially resectable tumors. In advanced stages, SCLC-like chemotherapy seems the best option of treatment, with a good response rate but a poor overall survival (from 8 to 16 months in different case series). New agents are under clinical investigation to improve LCNEC patients' outcome. We reviewed all data on treatment options feasible for pulmonary LCNEC, both for localized and extensive disease.
Source: Journal of Thoracic Oncology
Institution: University of Campania "Luigi Vanvitelli"
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: large cell neuroendocrine carcinoma, lung neuroendocrine tumors, small cell lung cancer, epidemiology, immunohistochemistry, neuroendocrine markers, prognosis, postoperative recurrence, primary resection, neoadjuvant chemotherapy, platinum-based chemotherapy, chemotherapy response, overall survival
Open Access status: hybrid
Estimated APC paid: $4,100
OpenAlex ID: W647594952
